>
Switch to:

Allergy Therapeutics Return-on-Tangible-Equity

: -50.31% (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Allergy Therapeutics's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2021 was $-33.8 Mil. Allergy Therapeutics's average shareholder tangible equity for the quarter that ended in Jun. 2021 was $67.2 Mil. Therefore, Allergy Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2021 was -50.31%.

The historical rank and industry rank for Allergy Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:

OTCPK:AGYTF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -48.03   Med: 6.41   Max: 21.29
Current: 6.31

-48.03
21.29

During the past 13 years, Allergy Therapeutics's highest Return-on-Tangible-Equity was 21.29%. The lowest was -48.03%. And the median was 6.41%.

OTCPK:AGYTF's Return-on-Tangible-Equity is ranked higher than
51% of the 966 Companies
in the Drug Manufacturers industry.

( Industry Median: 6.10 vs. OTCPK:AGYTF: 6.31 )

Allergy Therapeutics Return-on-Tangible-Equity Historical Data

The historical data trend for Allergy Therapeutics's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Return-on-Tangible-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.50 -36.15 13.41 19.56 7.34

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.96 78.06 -37.41 65.91 -50.31

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Return-on-Tangible-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Return-on-Tangible-Equity falls into.



Allergy Therapeutics Return-on-Tangible-Equity Calculation

Allergy Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2021 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2021 )  (A: Jun. 2020 )(A: Jun. 2021 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2021 )  (A: Jun. 2020 )(A: Jun. 2021 )
=4.0476858345021/( (48.869837296621+61.403927068724 )/ 2 )
=4.0476858345021/55.136882182672
=7.34 %

Allergy Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2021 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2021 )  (Q: Dec. 2020 )(Q: Jun. 2021 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2021 )  (Q: Dec. 2020 )(Q: Jun. 2021 )
=-33.809256661992/( (72.997311827957+61.403927068724)/ 2 )
=-33.809256661992/67.20061944834
=-50.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is two times the semi-annual (Jun. 2021) net income attributable to common stockholders data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Allergy Therapeutics  (OTCPK:AGYTF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Allergy Therapeutics Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)